In this special bonus episode, hosts Terry Turner and Christian Simmons revisit the topic of GLP-1 drugs to dive into emerging health concerns for Saxenda and Victoza.

New research has uncovered a potential link between liraglutide, the active ingredient in those drugs, and permanent vision loss.

To better understand the impact of this issue, Terry and Christian once again speak with attorney Danielle Gold from Weitz & Luxenberg, who is working on vision loss cases involving GLP-1s.Learn more at ⁠Drugwatch.com⁠.

GLP-1 drugs like Ozempic and Wegovy have reshaped how we treat obesity and diabetes — but what’s on the horizon? In this final episode of Beyond the Scale: The Ozempic Effect, hosts Terry Turner and Christian Simmons explore the future of these groundbreaking medications through insights from top experts.

Dr. William Hsu discusses the possibility of diabetes remission without lifelong medications. Dr. Elizabeth Van Dril sees GLP-1s becoming standard care, while Dr. Ashley Dwyer warns about disordered eating habits.

Dr. Lauren Cunningham emphasizes the importance of metabolic health over numbers on a scale. Rob Andrews explains how Medicare must adopt value-based pricing to ensure cost-effective access. And Dr. Steve Boyd warns that, unless we fix the healthcare system, the GLP-1 surge may not be sustainable.

Whether you’re taking these drugs, considering them, or just following the conversation, this episode offers essential insights into what lies ahead.

Learn more at Drugwatch.com.

In this revealing episode, hosts Terry Turner and Christian Simmons dive into the side effects and emerging lawsuits surrounding popular GLP-1 drugs like Ozempic, Wegovy and Mounjaro. Clinical pharmacist Dr. Lauren Cunningham breaks down how these medications work, their common side effects and when patients should be cautious. Health coach and former pharmacist Dr. Ashley Dwyer shares practical advice for managing side effects and preventing weight regain.

The episode also features attorney Danielle Gold from Weitz & Luxenberg, who is helping lead lawsuits claiming Novo Nordisk failed to warn users about serious risks, including stomach paralysis and NAION — a rare, irreversible vision loss condition. As GLP-1 medication use rises dramatically, this episode explores the health risks, legal battles and what patients should know before starting these medications.

Learn more at Drugwatch.com.